Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of “Moderate Buy” from Analysts

Arvinas, Inc. (NASDAQ:ARVNGet Rating) has been assigned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $96.19.

ARVN has been the topic of a number of research reports. Stifel Europe lowered their target price on Arvinas from $85.00 to $82.00 and set a “buy” rating on the stock in a research report on Thursday, May 5th. Wedbush lowered Arvinas from an “outperform” rating to a “neutral” rating and set a $43.00 target price on the stock. in a research report on Monday, May 9th. Piper Sandler decreased their price target on Arvinas from $116.00 to $76.00 and set an “overweight” rating for the company in a report on Monday, May 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Friday, April 1st. Finally, The Goldman Sachs Group decreased their price target on Arvinas from $111.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, May 24th.

Shares of NASDAQ:ARVN opened at $39.49 on Thursday. Arvinas has a twelve month low of $34.90 and a twelve month high of $108.46. The stock’s 50 day moving average is $47.45 and its 200-day moving average is $62.04.

Arvinas (NASDAQ:ARVNGet Rating) last issued its earnings results on Thursday, May 5th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.29). Arvinas had a negative return on equity of 29.38% and a negative net margin of 326.72%. The firm had revenue of $24.20 million for the quarter, compared to analyst estimates of $25.51 million. The firm’s revenue for the quarter was up 340.0% compared to the same quarter last year. Equities analysts predict that Arvinas will post -4.36 EPS for the current fiscal year.

In other news, Director Briggs Morrison sold 20,960 shares of the stock in a transaction on Thursday, April 14th. The stock was sold at an average price of $66.44, for a total transaction of $1,392,582.40. Following the completion of the transaction, the director now owns 19,976 shares in the company, valued at approximately $1,327,205.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.78% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of ARVN. Advisor Group Holdings Inc. grew its stake in shares of Arvinas by 142.7% during the 3rd quarter. Advisor Group Holdings Inc. now owns 415 shares of the company’s stock worth $34,000 after acquiring an additional 244 shares during the period. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Arvinas during the 3rd quarter worth about $41,000. First Quadrant L P CA purchased a new stake in Arvinas during the 4th quarter worth about $47,000. Lindbrook Capital LLC purchased a new stake in Arvinas during the 4th quarter worth about $57,000. Finally, Lazard Asset Management LLC purchased a new stake in Arvinas during the 1st quarter worth about $57,000. Institutional investors own 84.52% of the company’s stock.

About Arvinas (Get Rating)

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

Further Reading

Analyst Recommendations for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with's FREE daily email newsletter.